Psychedelic Spotlight News

New Study Explores If Ayahuasca Changes Personality Like Other Psychedelics

August 18, 2021June 2, 2024 Learn, Research

Recent ayahuasca study concludes mixed messages in attempt to determine if the ancient plant medicine has power to change personality, as psilocybin has shown.

Revive Therapeutics Is Exploring This Mushroom’s Potential to Treat Aggressive Breast Cancer

August 18, 2021June 2, 2024 Learn, Research, Treatment

The company is also pursuing psilocybin as a possible treatment for rare cancers, but they see huge potential in researching the medicinal effects of the reishi mushroom.

Interview with Evan Levine, PsyBio Therapeutics

August 18, 2021June 2, 2024 Listen, Podcasts

In this episode of the Psychedelic Spotlight podcast, we spotlight Evan Levine, Chairman & CEO of PsyBio Therapeutics, an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health issues and other disorders.

Why PsyBio Is Using Biosynthetic Psilocybin, Not Mushrooms, to Build Better Therapeutics

August 17, 2021June 2, 2024 Business, Learn

“A mushroom is not a pharmaceutical product,” CEO Evan Levine stresses, and explains why his company’s method of biologically engineering psilocybin is “cheaper, faster, greener.”

Canada Green Lights Country’s Third Clinical Psilocybin Study

August 17, 2021June 2, 2024 Learn, Research

The trial will build on Diamond Therapeutic’s previous animal research that demonstrated how non-hallucinogenic doses of psilocybin hold the potential to treat psychiatric disorders, including anxiety and depression.

MindMed’s Q2 Earnings Call: What does the future hold for MNMD/ MMED?

August 17, 2021June 2, 2024 Listen, Videos

Check out atai Life Sciences’ earnings call: https://www.youtube.com/watch?v=lkE3EmU0o_w

What’s up psychedelic stocks investors?!? Today marked MindMed’s (MNMD /MMED) Second Quarter 2021 conference call. In the conference call, MindMed gave updates on their varying projects, such as treating anxiety with LSD, addiction with 18MC, and pain with LSD. They also give insights into their digital medicines division and gave an update on their hiring spree.

This Kevin O’Leary-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 17+ different projects under their belt, MindMed is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is MNMD stock a good investment? Will MMED go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

Enjoy the episode!

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#MindMed #MNMD #PsychedelicStocks

‘Have A Good Trip’ Director Donick Cary Prepares a Second Dose: ‘The Adventures Continue’

August 16, 2021June 2, 2024 Culture, Learn

The filmmaker behind the Netflix hit tells us a sequel or a series is on the way, as well as which celebrities may share more psychedelic adventures.

Beckley Psytech Raises $80 Million to Fund Psychedelic Research Pipeline

August 16, 2021June 2, 2024 Business, Learn, Research

The company will use proceeds of the fundraising round to complete its ongoing Phase 1B trial on low-dose psilocybin in patients suffering from a rare headache condition with no approved medications to treat it.

First Neuroimaging Study of Psilocybin Microdosing Underway in Sydney

August 16, 2021June 2, 2024 Learn, Microdosing, Research

Researchers hope to establish whether the effects of microdosing are as profound as people say they are, since previous studies could not rule out placebo effect.

atai Life Sciences Q2 Conference Call and Questions & Answer Period: BIG NEWS for Psychedelic Stocks

August 16, 2021June 2, 2024 Listen, Videos

What’s up psychedelic stocks investors?!? Today marked atai Life Science’s (Nasdaq: atai) first-ever conference call, for Quarter 2, 2021. In the conference call, atai Life Sciences gave updates on their varying projects, ranging from attempting to treat depression, to cognitive impairment associated with schizophrenia. They also give insights on atai’s digital medicines division and answer investor’s questions at the end of the call.

This Peter Thiel-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 10+ different projects under their belt, atai is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is atai stock a good investment? Will atai go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?